Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing
Axsome shares jumped 22.9% to $182.64 after the FDA granted priority review for its AXS-05 filing in Alzheimer’s agitation, setting an April 30, 2026 action date. The stock traded between $148.79 and $184.40 on Wednesday with volume at 3.1 million. Mizuho raised its price target to $217 following the regulatory updates.